Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Paulo G. Kotze"'
Autor:
Thaisa Kowalski Furlan, Marcello Imbrizi, Daniela Magro, Paula C. Senger de Castro, Rodrigo Bremer Nones, Eron Fabio Miranda, Paulo G. Kotze
Publikováno v:
Journal of Coloproctology, Vol 44, Iss 03, Pp e187-e195 (2024)
Introduction and Objectives Certolizumab Pegol (CZP) is an anti-TNF agent approved in Brazil for Crohn's disease (CD). There is a lack of data in Brazil and Latin America detailing real-world experiences with CZP. The primary objective was clinical r
Externí odkaz:
https://doaj.org/article/824343b1774646e0be3b27e0774e6b7c
Autor:
David T. Rubin, Leonardo Salese, Mitchell Cohen, Paulo G. Kotze, John C. Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Objective: To assess colectomy incidence rates (IRs) and baseline characteristics for the presence of identified colectomy risk fac
Externí odkaz:
https://doaj.org/article/4f14d6481d204724942026dae5b142a5
Autor:
Abel B. Quaresma, Aderson O.M.C. Damiao, Claudio S.R. Coy, Daniela O. Magro, Adriano A.F. Hino, Douglas A. Valverde, Remo Panaccione, Stephanie B. Coward, Siew C. Ng, Gilaad G. Kaplan, Paulo G. Kotze
Publikováno v:
The Lancet Regional Health. Americas, Vol 13, Iss , Pp 100298- (2022)
Summary: Background: Population-based data on epidemiology of Inflammatory Bowel Diseases (IBD) in Brazil are scarce. This study aims to define temporal trends of incidence and prevalence rates of Crohn's disease (CD) and ulcerative colitis (UC) in B
Externí odkaz:
https://doaj.org/article/a7d5e271f4e9493dbb013360e71e7f28
Autor:
David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo G. Kotze, Marcia Pinheiro, Rajiv Mundayat, Eric Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R. Vavricka, Gary R. Lichtenstein
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Introduction: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with
Externí odkaz:
https://doaj.org/article/e097ca53b86849d19e2e7355909c6a94
Autor:
Marley R. Feitosa, Rogério S. Parra, Vanessa F. Machado, Gustavo N. Vilar, Jussara C. Aquino, José J. R. Rocha, Paulo G. Kotze, Omar Féres
Publikováno v:
Gastroenterology Research and Practice, Vol 2021 (2021)
Background and Aims. Patients may experience complications of Crohn’s disease (CD) even when treated with optimal medical therapy strategies. Previous data have shown the efficacy of hyperbaric oxygen therapy (HBOT) in the management of complicated
Externí odkaz:
https://doaj.org/article/cc5e8fd06ebb4071803bb4ca1c76e418
Autor:
Silvio Danese, Rupa Banerjee, JR Fraser Cummings, Iris Dotan, Paulo G Kotze, Rupert Wing Loong Leong, Kristine Paridaens, Laurent Peyrin-Biroulet, Glyn Scott, Gert Van Assche, Jan Wehkamp, Jesús K Yamamoto-Furusho
Publikováno v:
Intestinal Research, Vol 16, Iss 4, Pp 522-528 (2018)
Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare
Externí odkaz:
https://doaj.org/article/c5c9bafdb482423aaf5c56a8aa60cdab
Autor:
Ravi P, Kiran, Gursimran S, Kochhar, Revital, Kariv, Douglas K, Rex, Akira, Sugita, David T, Rubin, Udayakumar, Navaneethan, Tracy L, Hull, Huaibin Mabel, Ko, Xiuli, Liu, Lisa A, Kachnic, Scott, Strong, Marietta, Iacucci, Willem, Bemelman, Philip, Fleshner, Rachael A, Safyan, Paulo G, Kotze, André, D'Hoore, Omar, Faiz, Simon, Lo, Jean H, Ashburn, Antonino, Spinelli, Charles N, Bernstein, Sunanda V, Kane, Raymond K, Cross, Jason, Schairer, James T, McCormick, Francis A, Farraye, Shannon, Chang, Ellen J, Scherl, David A, Schwartz, David H, Bruining, Jessica, Philpott, Stuart, Bentley-Hibbert, Dino, Tarabar, Sandra, El-Hachem, William J, Sandborn, Mark S, Silverberg, Darrell S, Pardi, James M, Church, Bo, Shen
Publikováno v:
The Lancet Gastroenterology & Hepatology. 7:871-893
Surveillance pouchoscopy is recommended for patients with restorative proctocolectomy with ileal pouch-anal anastomosis in ulcerative colitis or familial adenomatous polyposis, with the surveillance interval depending on the risk of neoplasia. Neopla
Autor:
Hassan Azhari, James A. King, Stephanie Coward, Joseph W. Windsor, Christopher Ma, Shailja C. Shah, Siew C. Ng, Joyce W.Y. Mak, Paulo G. Kotze, Shomron Ben-Horin, Edward V. Loftus, Charlie W. Lees, Richard Gearry, Johan Burisch, Peter L. Lakatos, Xavier Calvet, Francisco Javier Bosques Padilla, Fox E. Underwood, Gilaad G. Kaplan
Publikováno v:
American Journal of Gastroenterology. 117:1419-1427
Peptic ulcer disease (PUD) is a common cause of hospitalization worldwide. We assessed temporal trends in hospitalization for PUD in 36 Organisation for Economic Co-operation and Development (OECD) countries since the turn of the 21st century.The OEC
Autor:
Lucas Guillo, Maria Abreu, Remo Panaccione, William J Sandborn, Valderilio F Azevedo, Lianne Gensler, Bahar Moghaddam, Vineet Ahuja, Sabrina A Ali, Matthieu Allez, Ashwin N Ananthakrishnan, Abhik Bhattacharya, Marla Dubinsky, Anne Griffiths, Ailsa Hart, Burton Korelitz, Paulo G Kotze, Ioannis E Koutroubakis, Peter L Lakatos, James O Lindsay, Fernando Magro, Gerassimos J Mantzaris, Siew C Ng, Colm O'Morain, Julian Panés, Tommaso Parigi, Zhihua Ran, Gerhard Rogler, David T Rubin, David B Sachar, Britta Siegmund, Flavio Steinwurz, Curt Tysk, Stephan Vavricka, Sofia G Verstraete, Antoine P Brezin, Anna K Haemel, Axel Dignass, Bruce E Sands, Silvio Danese, Laurent Peyrin-Biroulet
Publikováno v:
The Lancet Gastroenterology & Hepatology. 7:254-261
Extraintestinal manifestations occur frequently in patients with inflammatory bowel disease (IBD) and remain a diagnostic and therapeutic challenge. The aim of the Endpoints for Extraintestinal Manifestations in Inflammatory Bowel Disease Trials (EXT
Autor:
Michael J. Buie, Joshua Quan, Joseph W. Windsor, Stephanie Coward, Tawnya M. Hansen, James A. King, Paulo G. Kotze, Richard B. Gearry, Siew C. Ng, Joyce W.Y. Mak, Maria T. Abreu, David T. Rubin, Charles N. Bernstein, Rupa Banerjee, Jesus K. Yamamoto-Furusho, Remo Panaccione, Cynthia H. Seow, Christopher Ma, Fox E. Underwood, Vineet Ahuja, Nicola Panaccione, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Gilaad G. Kaplan, Domingo Balderramo, Vui Heng Chong, Fabián Juliao-Baños, Usha Dutta, Marcellus Simadibrata, Jamilya Kaibullayeva, Yang Sun, Ida Hilmi, Raja Affendi Raja Ali, Mukesh Sharma Paudel, Mansour Altuwaijri, Juanda Leo Hartono, Shu Chen Wei, Julajak Limsrivilai, Sara El Ouali, Beatriz Iade Vergara, Viet Hang Dao, Paul Kelly, Phoebe Hodges, Yinglei Miao, Maojuan Li
Publikováno v:
Clinical Gastroenterology and Hepatology.
The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis